MMS

What happens when data is better prioritised?

Drug development is rife with complexities. Success hinges upon managing them effectively. Data is the ultimate deliverable of any study, and treating it with the utmost focus is a responsibility owed to study participants and, ultimately, future patients. This has become even more important as the complexity of clinical trial data structures and collection modalities has proliferated. Clinical Trials Insight speaks with Ben Dudley chief commercial officer at MMS, a data-focused CRO with operations across the United States, about a new approach to integrating biometrics and regulatory aspects of the industry.